• The Role of Stem Cells in Cancer Progression and Therapy
  • Zahra shakeri,1,*
    1. BA student, Tehran, Azad University, Shahr Ray branch


  • Introduction: Primary cancer cells have been found to derive from stem cells, with a subsection of these cells named “cancer stem cells” (CSC’s). CSCs replicate similar characteristics to regular stem cells, such as the ability to proliferate in their microenvironments. CSCs sustain cancer by promoting proliferation and therefore must be targeted when attempting to eliminate cancer for successful and long-lasting results. As do most healthy cells. This study's objective was The Role of Stem Cells in Cancer Progression and Therapy.
  • Methods: This review study has written the Role of Stem Cells in Cancer Progression and Therapy from scientific databases such as Science Direct, Springer, Google Scholar, and PubMed.
  • Results: The results show performed simultaneous silencing of CD-47 and PD-L1 in order to enhance immunotherapy against circulating tumor cells. Inhibiting PD-L1 allowed immune cells to locate tumor cells more adequately, and blockade of CD-47 permitted macrophage-mediated destruction of the tumor cells. In vitro flow, cytometry confirmed overexpression of CD-47 and PD-L1 in the tumor cell line.19 Compared to the blank controls or single-antibody group, dual inhibition of these immunosuppressive proteins resulted in a more potent reduction of solid tumors in mice. In order to target CD-47 and silence its downstream effects, various forms of pharmacological and nanomedicine-based approaches have been established. An antibody named Hu5F9-G4 that targets CD-47, allowing macrophages to destroy the cancer cells, has been developed. Another similar antibody, Rituximab, which has been known to amplify destruction signals inhibited by CD-47 positively, is highly active and is well tolerated as first-line single-agent therapy for indolent non-Hodgkin lymphoma (NHL). Using the application of both antibodies, Hu5F9-G4 and Rituximab, the results of a clinically evaluated study on the treatment outcome in patients of NHL concluded that at least 50% of the test subjects had eliminated most symptoms of cancer.
  • Conclusion: Silencing cell surface markers on CSCs can promote immune recognition of tumor sites and inhibit the binding of tumor cargo to healthy cells, thus preventing their transformation. immunotherapy towards many forms of cancer by targeting cancer stem cells. This is because, in the past, various CSCs in cancers such as pancreatic, lung, and breast cancers have been proven to express CD-47. Hence, targeting this immune blockade molecule expressed in CSCs may provide a new avenue of cancer treatment.
  • Keywords: Stem Cells, Nanomaterials, Cancer Therapy